Literature DB >> 26467471

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).

S Gourgou-Bourgade, D Cameron, P Poortmans, B Asselain, D Azria, F Cardoso, R A'Hern, J Bliss, J Bogaerts, H Bonnefoi, E Brain, M J Cardoso, B Chibaudel, R Coleman, T Cufer, L Dal Lago, F Dalenc, E De Azambuja, M Debled, S Delaloge, T Filleron, J Gligorov, M Gutowski, W Jacot, C Kirkove, G MacGrogan, S Michiels, I Negreiros, B V Offersen, F Penault Llorca, G Pruneri, H Roche, N S Russell, F Schmitt, V Servent, B Thürlimann, M Untch, J A van der Hage, G van Tienhoven, H Wildiers, J Yarnold, F Bonnetain, S Mathoulin-Pélissier, C Bellera, T S Dabakuyo-Yonli.   

Abstract

Entities:  

Year:  2015        PMID： 26467471     DOI： 10.1093/annonc/mdv478

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  15 in total

1.  Distribution and influence of the 21-gene recurrence score on chemotherapy decision-making in special type of breast cancer.

Authors:  Jing Yu; Jiayi Wu; Ou Huang; Jianrong He; Li Zhu; Weiguo Chen; Yafen Li; Xiaosong Chen; Kunwei Shen
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

2.  Impact of baseline telomere length on survival and chemotherapy related toxicity in breast cancer patients receiving (neo)adjuvant anthracycline containing chemotherapy.

Authors:  Sigrid Hatse; Marta Serena; Christof Vulsteke; Kevin Punie; Patrick Neven; Ann Smeets; Annouschka Laenen; Hans Wildiers
Journal:  Transl Oncol       Date:  2022-10-08       Impact factor: 4.803

3.  Impact of financial support on the prognosis of HER2-positive breast cancer from 2002 to 2020: a prospective cohort from western China.

Authors:  Dan Zheng; Linlin Song; Xu Liu; Xiaorong Zhong; Yuxin Xie; Chengshi Wang; Ping He; Xi Yan; Tinglun Tian; Hong Zheng; Ting Luo
Journal:  Gland Surg       Date:  2022-05

Review 4.  Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer - a review of current evidence for and against the use of anti-HER2 treatment regimens.

Authors:  Kai Cc Johnson; Dionisia Quiroga; Preeti Sudheendra; Robert Wesolowski
Journal:  Expert Rev Anticancer Ther       Date:  2022-04-20       Impact factor: 3.627

5.  Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer.

Authors:  Hai-Yuan Yang; Ding Ma; Yi-Rong Liu; Xin Hu; Jian Zhang; Zhong-Hua Wang; Gen-Hong Di; Xi-Chun Hu; Zhi-Ming Shao
Journal:  Sci Rep       Date:  2017-04-25       Impact factor: 4.379

6.  Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.

Authors:  Elsa Curtit; Xavier Pivot; Julie Henriques; Sophie Paget-Bailly; Pierre Fumoleau; Maria Rios; Hervé Bonnefoi; Thomas Bachelot; Patrick Soulié; Christelle Jouannaud; Hugues Bourgeois; Thierry Petit; Isabelle Tennevet; David Assouline; Marie-Christine Mathieu; Jean-Philippe Jacquin; Sandrine Lavau-Denes; Ariane Darut-Jouve; Jean-Marc Ferrero; Carole Tarpin; Christelle Lévy; Valérie Delecroix; Véronique Trillet-Lenoir; Oana Cojocarasu; Jérôme Meunier; Jean-Yves Pierga; Pierre Kerbrat; Céline Faure-Mercier; Hélène Blanché; Mourad Sahbatou; Anne Boland; Delphine Bacq; Céline Besse; Gilles Thomas; Jean-François Deleuze; Iris Pauporté; Gilles Romieu; David G Cox
Journal:  Breast Cancer Res       Date:  2017-08-22       Impact factor: 6.466

7.  Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?

Authors:  Sherko Kümmel; Christian Jackisch; Volkmar Müller; Andreas Schneeweiss; Sandra Klawitter; Michael P Lux
Journal:  Cancer Manag Res       Date:  2018-11-08       Impact factor: 3.989

8.  Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.

Authors:  Yi Chen; Kai Chen; Xiaoyun Xiao; Yan Nie; Shaohua Qu; Chang Gong; Fengxi Su; Erwei Song
Journal:  BMC Cancer       Date:  2016-05-19       Impact factor: 4.430

9.  Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.

Authors:  Chang Gong; Weige Tan; Kai Chen; Na You; Shan Zhu; Gehao Liang; Xinhua Xie; Qian Li; Yunjie Zeng; Nengtai Ouyang; Zhihua Li; Musheng Zeng; ShiMei Zhuang; Wan-Yee Lau; Qiang Liu; Dong Yin; Xueqin Wang; Fengxi Su; Erwei Song
Journal:  EBioMedicine       Date:  2016-08-17       Impact factor: 8.143

10.  Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies.

Authors:  Shani Paluch-Shimon; Nathan I Cherny; Elisabeth G E de Vries; Urania Dafni; Martine J Piccart; Nicola Jane Latino; Fatima Cardoso
Journal:  ESMO Open       Date:  2020-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.